NASDAQ
64.55USD
+1.11 (+1.75%)
We have scored 4 news catalysts on Sol-Gel Technologies Ltd. (SLGL) over the past 12 months. The biggest single-day move next to one of them came Mar 24, 2026, when SLGL closed +20.9%: “Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering”. Coverage across the window leans positive (average ticker sentiment +0.57). Most of the impact sits in price momentum and institutional ownership change.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
208.8M
P/E
—
EPS
—
Beta
1.13
52W range
23.16-97.97
Day range
62.64–64.73
Open
63.02
Prev close
63.44
Volume
30.9K
Avg volume
46.2K
Dividend
0.00
IPO
2018-02-01
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Sol-Gel Technologies Ltd. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for SLGL: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
